This study was designed to test if nitric oxide (NO) 
INTRODUCTION
Nitric oxide (NO) formed from L-arginine and released from endothelium causes relaxation of vascular smooth muscle via a cGMP mechanism (17). NO release can be triggered by receptor-mediated mechanisms and by physical stimuli such as endothelial shear stress and mechanical deformation (22, 32) . In-vitro studies show that NO depresses oxidative metabolism (23, 36, 40, 46) . However, in-vivo studies have yielded conflicting results on the effects of NO on myocardial oxygen consumption (1, 3, 6, 15, 20, 31, 33, 35, 38, 43) .
NO synthesis inhibition has been frequently used to evaluate NO-mediated mechanisms. In working left ventricle, NO synthesis inhibition has yielded inconsistent findings regarding NO-mediated control of coronary blood flow (1, 3, 4, 9, 11, 27, 37, 43, 45) and myocardial oxygen consumption (MVO 2 ; (1, 3, 6, 15, 20, 31, 33, 38, 43) . In working right ventricle, NO synthesis inhibition reduces resting right coronary blood flow 
METHODS

Surgical Preparation
This investigation was approved by the Institutional Animal Care and Use Committee and was conducted in accordance with the Guide for the Care and Use of Laboratory Animals (NIH publication No. 85-23, revised 1996) . Five adult dogs of either sex, free of clinically evident disease, were used for this study. The dogs were fasted overnight, and then anesthetized with sodium pentobarbital (30 mg/kg, i.v.).
Supplemental pentobarbital was administered as needed to maintain stable anesthesia.
After intubation, the dogs were ventilated by a Harvard respirator with room air supplemented with oxygen to maintain normal arterial blood gases throughout the experiment. A saline-filled vinyl catheter was inserted into the thoracic aorta via a femoral artery to measure aortic pressure. In the other femoral artery, a saline-filled vinyl catheter was placed to withdraw blood to supply an extracorporeal coronary perfusion circuit. A saline-filled vinyl catheter was inserted into a femoral vein for administration of supplementary anesthetic and heparin. The right heart was exposed through a right thoracotomy in the fourth intercostal space and suspended in a pericardial cradle. A Millar catheter-tip pressure transducer was inserted through the right atrial appendage and advanced across the tricuspid valve to measure right ventricular pressure and dP/dt.
The right coronary artery was isolated near its origin, and after heparinization (500 U/kg, i.v.), was cannulated with a stainless steel cannula (2.1 mm o.d., 1.4 mm i.d.). The right coronary artery was perfused with arterial blood from a pressurized reservoir, which was supplied with blood from a femoral artery. This perfusion tubing was equipped with a heat exchanger to maintain coronary perfusate temperature To collect right coronary venous blood samples, a 24 G i.v. catheter was inserted into a superficial vein on the right ventricular epicardial surface. A previous study from this laboratory showed that contamination of this venous blood with blood from sources other than the right coronary artery is less than 3% for the right coronary artery perfusion pressure of 100 mmHg used in these experiments (25). The right coronary venous blood was allowed to drain freely into a beaker and was returned to the dog periodically. Arterial and venous blood samples were collected anaerobically and Right ventricular MVO 2 and lactate uptake were calculated from the product of coronary blood flow times the respective right coronary arteriovenous difference. Right ventricular mechanical function was estimated from the triple product: heart rate X right ventricular dP/dt max X peak right ventricular systolic pressure (3) . The relationship between right ventricular MVO 2 and the triple product reflects the oxygen cost of right ventricular mechanical function.
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Experimental protocol
Right coronary perfusion pressure was maintained at 100 mmHg throughout the experimental protocol, so that pressure-induced changes in right ventricular MVO 2 (14) were avoided. Baseline measurements were obtained after allowing 20 min for recovery from surgical procedures and stabilization of the preparation. After recording baseline measurements, graded doses of norepinephrine ranging from 0.01 to 0.20 :g/kg/min were infused into the right coronary perfusion line by a Harvard infusion pump. All dogs received norepinephrine infusions of 0.050, 0.075, and 0.100 :g/kg/min before and during L-NAME treatment. Arterial and right coronary venous blood samples were collected, and hemodynamic and cardiac function variables were recorded when steady state conditions were achieved (~3 min) at each norepinephrine infusion. After the final pre-treatment infusion of norepinephrine, the infusion pump was stopped and 15-20 min were allowed for hemodynamic variables to return to baseline values.
Subsequently, L-NAME (150 :g/min) was continuously infused into the right coronary artery perfusion line. Fifteen minutes after initiation of the intracoronary L-NAME infusion, baseline measurements were obtained and the norepinephrine infusion response protocol was repeated. After the final infusion of norepinephrine, the L-NAME infusion was stopped. After stabilization of hemodynamic and cardiac function, Evans blue dye was injected into the right coronary perfusion line. When the right ventricle was visibly dyed, the heart was electrically fibrillated to terminate the experiment. The heart was excised, and the dyed tissue was carefully excised and weighed, so that coronary blood flow and MVO 2 could be normalized per gram of tissue mass.
The dose of L-NAME (150 µg/min, i.c.) used to block NO synthesis was previously found to reduce coronary vasodilation to acetylcholine (20 µg i.c.) by ~65% in the right ventricle (35) and in the left ventricle (6, 26) . Complete blockade of acetylcholine-mediated vasodilation was not anticipated because acetylcholine causes vasodilation by additional, non-NO dependent mechanisms (12) .
Statistical Analyses
All values are presented as mean ± SE. Effects of L-NAME at norepinephrine 
Results
Baseline arterial blood gas variables were: pH = 7.41 ± 0.01; PO 2 = 103 ± 3; PCO 2 = 33 ± 2; Hct = 38 ± 4. None of these variables were significantly affected by graded right coronary infusions of norepinephrine in the absence or presence of NO synthesis inhibition with L-NAME. Right coronary venous pH, PO 2 , PCO 2 values are reported in the table. Venous pH was reduced by L-NAME, and venous PO 2 was reduced by norepinephrine and by L-NAME. Venous PCO 2 was increased by L-NAME.
Right ventricular uptake of lactate was not significantly affected by either norepinephrine or L-NAME. Hemodynamic and right ventricular function variables are summarized in the Table. Mean aortic blood pressure was unaffected by norepinephrine or L-NAME.
Right ventricular MVO 2 , heart rate, right ventricular peak systolic pressure, right ventricular dP/dt max , and triple product were increased by norepinephrine infusion in the absence and presence of L-NAME treatment. After L-NAME treatment triple product L-NAME (P = 0.38), there was a significant (P < 0.0001) decrease in coronary venous PO 2 at a given level of MVO 2. In addition, right coronary venous PO 2 was reduced by 12% at baseline, and was further reduced by 28% at the highest dose of norepinephrine following L-NAME treatment (see table) . These data indicate that the inhibition of NO synthesis at higher levels of MVO 2 forced the right ventricle to call upon its extraction reserve to meet the increase in metabolic demand. 
Effects of NO on right coronary blood flow
As expected, right coronary blood flow increased with graded norepinephrine infusions. In this investigation, right coronary perfusion pressure was held constant, so changes in coronary blood flow reflect chances in vascular conductance. An important
regulatory role for NO in right coronary blood flow control is evident from the decreases in flow caused by NO synthesis inhibition (Fig. 1) . Furthermore, NO synthesis inhibition depressed the right coronary blood flow vs. right ventricular MVO 2 relationship (Fig. 2A) .
The significantly steeper slope of this relationship before L-NAME indicates that NO production is increased as myocardial oxygen demand is elevated. This increase in NO production is most likely due to increases in coronary vascular shear stress associated with elevated right coronary blood flow at the higher dose of norepinephrine. Thus, for the conditions of these experiments, NO provided a positive feedback mechanism that enhanced oxygen delivery to right ventricular myocardium. Coronary venous PO 2 is a sensitive index of changes in myocardial oxygen supply/demand balance. The reduction in coronary venous PO 2 at a given level of MVO 2 when NO synthesis was inhibited ( The mechanism by which norepinephrine stimulates NO production was not examined in the present investigation. However, earlier studies suggest that inotropic agents such as norepinephrine stimulate coronary β 2 and/or α 2 adrenoceptors, which augments NO release from coronary endothelial cells (5, 24, 27, 41) . This vasodilator effect is independent of metabolic vasodilation mediated by increases in MVO 2 and could be responsible for the significant effect of NO on right coronary blood flow control.
Effects of NO on right ventricular MVO 2
As expected, right ventricular MVO 2 increased with graded norepinephrine infusions (Fig. 3B) . These increases resulted from $-adrenergic receptor-mediated increases in heart rate, right ventricular dP/dt max , and systolic pressure as reflected in the triple product (heart rate X right ventricular peak systolic pressure X right ventricular dP/dt; see Table) . The increase in right ventricular MVO 2 as a function of norepinephrine dose was not altered by NO synthesis inhibition (Fig. 3B ). 
Effects of NO on right ventricular function
In the present study, both L-NAME and norepinephrine were administered into the right coronary arterial circulation, and systemic hemodynamic perturbations were avoided as demonstrated by stable mean aortic blood pressure. However, heart rate and right ventricular contractility were increased by norepinephrine infusion, so the triple product was used to index mechanical function. NO synthesis inhibition caused a reduction in the triple product at comparable norepinephrine doses (Fig. 3A) . This is consistent with the report of Bernstein et al. (3) that NO synthesis inhibition caused a reduction in the left ventricular triple product at comparable exercise intensities. These workers offered no explanation for this important mechanical response to NO synthesis inhibition.
In the current investigation, the blunting of the mechanical response to norepinephrine caused by NO synthesis inhibition might have been related to the concurrent reduction of right coronary blood flow. Since there was no change in right ventricular MVO 2 or lactate uptake, the reduction in mechanical function was not due to inadequate blood flow and oxygen supply. A more likely explanation is that factors affecting myocardial contractility were released by coronary endothelium in response to changes in coronary blood flow (28, 29).
Why did MVO 2 remain constant in the current study and in that of Bernstein et al. 
Potential limitation of the study
It should be pointed out that NO or its stable metabolites were not measured in this study. Thus, the extent to which our dose of L-NAME decreased NO production is unclear. However, Node et al. measured stable metabolites of NO after intracoronary L-NAME (~150-230 :g/min) in the left ventricle and found that L-NAME significantly attenuated the rise in NO production following stimulation of the left ventricle with intracoronary isoproterenol and CaCl 2 (26). In addition, the dose of L-NAME used in this study also decreased the vasodilation to acetylcholine (20 :g i.c.) by ~65% (35).
Therefore, we feel NO synthase was adequately inhibited in this investigation.
Conclusion
This is the first study to show that NO is an important regulator of right coronary ; RCA = Right coronary artery; RCV = Right coronary vein; LU = Lactate uptake; RV MVO 2 = Right ventricular myocardial oxygen consumption; * = Different from untreated control, same norepinephrine dose; a = Significant effect of norepinephrine infusion; b = Significant effect of L-NAME. in the absence and presence of L-NAME. L-NAME significantly depressed the relationship between RV mechanical performance and norepinephrine dose (P < 0.01),
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indicating that NO improves RV mechanical performance during norepinephrine infusion. However, L-NAME did not significantly alter the relationship between RV MVO 2 and norepinephrine. Fig. 4 . Relationship between right ventricular (RV) myocardial oxygen consumption (MVO 2 ) and RV mechanical work estimated from the triple product of heart rate X RV dP/dt max X peak RV systolic pressure, in the absence and presence of L-NAME. Values are mean ± SE. RV MVO 2 significantly increased with norepinephrine-induced increases in RV myocardial function in the absence and presence of L-NAME. L-NAME significantly elevated this relationship (P < 0.0001), indicating that NO reduces the oxygen cost during norepinephrine-mediated increases in RV mechanical function.
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